Nasalferon, drops

4 trials

Sponsors

Center for Genetic Engineering and Biotechnology (CIGB)

Conditions

Acute respiratory infection (ARI)COVID-19 COVID-19 SARS-CoV-2acute respiratory infection

Phase 3

Nasalferon in COVID-19

Active, not recruitingRPCEC00000399

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-11-22Target: 128Updated: 2026-03-30

Nasalferon in ARI

Active, not recruitingRPCEC00000407

Center for Genetic Engineering and Biotechnology (CIGB)Acute respiratory infection (ARI)

Start: 2022-09-01Target: 495Updated: 2026-03-30

Nasal recombinant human interferon alfa-2b in ARI

Active, not recruitingRPCEC00000412

Center for Genetic Engineering and Biotechnology (CIGB)acute respiratory infection

Start: 2023-02-01Target: 608Updated: 2026-03-30

Unknown Phase

Expanded Clinical Use of Nasalferon in COVID-19

Active, not recruitingRPCEC00000396

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-11-15Target: 200Updated: 2026-03-30